{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T23:24:13Z","timestamp":1794007453896,"version":"4.8.0"},"reference-count":98,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["gimjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Genetics in Medicine"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.gim.2024.101242","type":"journal-article","created":{"date-parts":[[2024,11,4]],"date-time":"2024-11-04T17:53:01Z","timestamp":1730742781000},"page":"101242","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Biomarker testing for lysosomal diseases: A technical standard of the American College of Medical Genetics and Genomics (ACMG)"],"prefix":"10.1016","volume":"27","author":[{"given":"Ashlee R.","family":"Stiles","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taraka R.","family":"Donti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia L.","family":"Hall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William R.","family":"Wilcox","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1-2","key":"10.1016\/j.gim.2024.101242_bib1","first-page":"1","article-title":"Lysosomal storage diseases","volume":"2","author":"Ferreira","year":"2017","journal-title":"Transl Sci Rare Dis"},{"issue":"24","key":"10.1016\/j.gim.2024.101242_bib2","doi-asserted-by":"crossref","first-page":"476","DOI":"10.21037\/atm.2018.11.39","article-title":"Lysosomal storage disease overview","volume":"6","author":"Sun","year":"2018","journal-title":"Ann Transl Med"},{"issue":"2","key":"10.1016\/j.gim.2024.101242_bib3","doi-asserted-by":"crossref","DOI":"10.1212\/NXG.0000000000000055","article-title":"Long-term follow-up and sudden unexpected death in Gaucher disease type 3 in Egypt","volume":"2","author":"Abdelwahab","year":"2016","journal-title":"Neurol Genet"},{"issue":"4","key":"10.1016\/j.gim.2024.101242_bib4","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/j.gim.2021.12.013","article-title":"Measurement of lysosomal enzyme activities: a technical standard of the American College of Medical Genetics and Genomics (ACMG)","volume":"24","author":"Strovel","year":"2022","journal-title":"Genet Med"},{"key":"10.1016\/j.gim.2024.101242_bib5","article-title":"ScreenPlus: a comprehensive, multi-disorder newborn screening program","volume":"38","author":"Kelly","year":"2024","journal-title":"Mol Genet Metab\u00a0Rep"},{"issue":"1","key":"10.1016\/j.gim.2024.101242_bib6","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.ymgme.2022.03.001","article-title":"The diagnosis and management of Gaucher disease in pediatric patients: where do we go from here?","volume":"136","author":"Weinreb","year":"2022","journal-title":"Mol Genet Metab"},{"issue":"2","key":"10.1016\/j.gim.2024.101242_bib7","first-page":"3","article-title":"Advances in diagnosis and management of Pompe disease","volume":"24","author":"Davison","year":"2020","journal-title":"J\u00a0Mother Child"},{"issue":"2","key":"10.1016\/j.gim.2024.101242_bib8","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1080\/17446651.2018.1445524","article-title":"Recent advances in the diagnosis and management of Gaucher disease","volume":"13","author":"Gary","year":"2018","journal-title":"Expert Rev Endocrinol Metab"},{"issue":"3","key":"10.1016\/j.gim.2024.101242_bib9","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1067\/mcp.2001.113989","article-title":"Biomarkers and surrogate endpoints: preferred definitions and conceptual framework","volume":"69","year":"2001","journal-title":"Clin Pharmacol Ther"},{"issue":"5","key":"10.1016\/j.gim.2024.101242_bib10","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/S0022-2275(20)36768-7","article-title":"Isolation and characterization of glucosylsphingosine from Gaucher\u2019s spleen","volume":"15","author":"Raghavan","year":"1974","journal-title":"J\u00a0Lipid Res"},{"issue":"9","key":"10.1016\/j.gim.2024.101242_bib11","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1055\/s-0028-1106231","article-title":"[Angiokeratoma corporis diffusum (Fabry\u2019s disease). Biochemical diagnosis in plasma]","volume":"100","author":"Atzpodien","year":"1975","journal-title":"Dtsch Med Wochenschr"},{"issue":"4650","key":"10.1016\/j.gim.2024.101242_bib12","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1126\/science.6719111","article-title":"Progressive accumulation of toxic metabolite in a genetic leukodystrophy","volume":"224","author":"Igisu","year":"1984","journal-title":"Science"},{"issue":"4","key":"10.1016\/j.gim.2024.101242_bib13","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1111\/j.1651-2227.1975.tb03896.x","article-title":"Chemical pathology of Krabbe\u2019s disease. III. Ceramide-hexosides and gangliosides of brain","volume":"64","author":"Vanier","year":"1975","journal-title":"Acta Paediatr Scand"},{"issue":"10","key":"10.1016\/j.gim.2024.101242_bib14","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1515\/bchm2.1980.361.2.1489","article-title":"Niemann-Pick disease, Type C: evidence for the deficiency of an activating factor stimulating sphingomyelin and glucocerebroside degradation","volume":"361","author":"Christomanou","year":"1980","journal-title":"Hoppe Seylers Z Physiol Chem"},{"issue":"2","key":"10.1016\/j.gim.2024.101242_bib15","first-page":"151","article-title":"Sphingomyelin storage in a patient with myoclonus epilepsy as a main clinical symptom \u2013 a varient in Niemann-Pick disease type C","volume":"49","author":"Kunishita","year":"1979","journal-title":"Jpn J Exp Med"},{"issue":"2","key":"10.1016\/j.gim.2024.101242_bib16","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1111\/j.1432-1033.1978.tb12098.x","article-title":"Glucose-containing oligosaccharides in the urine of patients with glycogen storage disease type II and type III","volume":"83","author":"Lennartson","year":"1978","journal-title":"Eur J Biochem"},{"issue":"1","key":"10.1016\/j.gim.2024.101242_bib17","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/s13023-020-01662-8","article-title":"A\u00a0new UHPLC-MS\/MS method for the screening of urinary oligosaccharides expands the detection of storage disorders","volume":"16","author":"Semeraro","year":"2021","journal-title":"Orphanet J Rare Dis"},{"issue":"10","key":"10.1016\/j.gim.2024.101242_bib18","doi-asserted-by":"crossref","first-page":"5326","DOI":"10.1073\/pnas.76.10.5326","article-title":"Enzyme therapy in Fabry disease: differential in\u00a0vivo plasma clearance and metabolic effectiveness of plasma and splenic alpha-galactosidase A isozymes","volume":"76","author":"Desnick","year":"1979","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"10.1016\/j.gim.2024.101242_bib19","first-page":"393","article-title":"Enzyme therapy XVII: metabolic and immunologic evaluation of alpha- galactosidase A replacement in Fabry disease","volume":"16","author":"Desnick","year":"1980","journal-title":"Birth Defects Orig Artic Ser"},{"issue":"2","key":"10.1016\/j.gim.2024.101242_bib20","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1111\/cge.13546","article-title":"Consensus recommendations for diagnosis, management and treatment of Fabry disease in paediatric patients","volume":"96","author":"Germain","year":"2019","journal-title":"Clin Genet"},{"issue":"5","key":"10.1016\/j.gim.2024.101242_bib21","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1007\/s10897-013-9613-3","article-title":"Fabry disease practice guidelines: recommendations of the National Society of Genetic Counselors","volume":"22","author":"Laney","year":"2013","journal-title":"J\u00a0Genet Couns"},{"issue":"4 suppl 5","key":"10.1016\/j.gim.2024.101242_bib22","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1053\/j.seminhematol.2004.07.010","article-title":"Gaucher disease type 1: revised recommendations on evaluations and monitoring for adult patients","volume":"41","author":"Weinreb","year":"2004","journal-title":"Semin Hematol"},{"issue":"5","key":"10.1016\/j.gim.2024.101242_bib23","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1097\/01.gim.0000218152.87434.f3","article-title":"Pompe disease diagnosis and management guideline","volume":"8","author":"Kishnani","year":"2006","journal-title":"Genet Med"},{"issue":"4","key":"10.1016\/j.gim.2024.101242_bib24","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1017\/cjn.2016.37","article-title":"Pompe disease: diagnosis and management. Evidence-based guidelines from a Canadian expert panel","volume":"43","author":"Tarnopolsky","year":"2016","journal-title":"Can J Neurol Sci"},{"issue":"1","key":"10.1016\/j.gim.2024.101242_bib25","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/s13023-018-0766-x","article-title":"Consensus guidelines for newborn screening, diagnosis and treatment of infantile Krabbe disease","volume":"13","author":"Kwon","year":"2018","journal-title":"Orphanet J Rare Dis"},{"issue":"4","key":"10.1016\/j.gim.2024.101242_bib26","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1136\/jmg-2022-108523","article-title":"Prevalence of Fabry disease-causing variants in the UK Biobank","volume":"60","author":"Gilchrist","year":"2023","journal-title":"J\u00a0Med Genet"},{"issue":"5","key":"10.1016\/j.gim.2024.101242_bib27","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1097\/GIM.0b013e318211a7e1","article-title":"Lysosomal storage diseases: diagnostic confirmation and management of presymptomatic individuals","volume":"13","author":"Wang","year":"2011","journal-title":"Genet Med"},{"issue":"11","key":"10.1016\/j.gim.2024.101242_bib28","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1097\/GIM.0b013e3181bb05bb","article-title":"Life expectancy and cause of death in males and females with Fabry disease: findings from the Fabry Registry","volume":"11","author":"Waldek","year":"2009","journal-title":"Genet Med"},{"issue":"1","key":"10.1016\/j.gim.2024.101242_bib29","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.pharmthera.2009.01.003","article-title":"Fabry disease","volume":"122","author":"Schiffmann","year":"2009","journal-title":"Pharmacol Ther"},{"issue":"1","key":"10.1016\/j.gim.2024.101242_bib30","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1111\/cge.12613","article-title":"X-chromosome inactivation in female patients with Fabry disease","volume":"89","author":"Echevarria","year":"2016","journal-title":"Clin Genet"},{"issue":"2","key":"10.1016\/j.gim.2024.101242_bib31","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.gene.2012.06.013","article-title":"X-inactivation in Fabry disease","volume":"505","author":"Elstein","year":"2012","journal-title":"Gene"},{"issue":"3","key":"10.1016\/j.gim.2024.101242_bib32","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.ymgme.2020.04.006","article-title":"A\u00a0comprehensive testing algorithm for the diagnosis of Fabry disease in males and females","volume":"130","author":"Stiles","year":"2020","journal-title":"Mol Genet Metab"},{"issue":"2","key":"10.1016\/j.gim.2024.101242_bib33","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.ymgme.2007.09.013","article-title":"Females with Fabry disease frequently have major organ involvement: lessons from the Fabry Registry","volume":"93","author":"Wilcox","year":"2008","journal-title":"Mol Genet Metab"},{"issue":"8","key":"10.1016\/j.gim.2024.101242_bib34","doi-asserted-by":"crossref","first-page":"2812","DOI":"10.1073\/pnas.0712309105","article-title":"Elevated globotriaosylsphingosine is a hallmark of Fabry disease","volume":"105","author":"Aerts","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"10.1016\/j.gim.2024.101242_bib35","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1038\/gim.2018.31","article-title":"Effectiveness of plasma lyso-Gb3 as a biomarker for selecting high-risk patients with Fabry disease from multispecialty clinics for genetic analysis","volume":"21","author":"Maruyama","year":"2019","journal-title":"Genet Med"},{"issue":"1-2","key":"10.1016\/j.gim.2024.101242_bib36","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.ymgme.2016.10.006","article-title":"Plasma LysoGb3: a useful biomarker for the diagnosis and treatment of Fabry disease heterozygotes","volume":"120","author":"Nowak","year":"2017","journal-title":"Mol Genet Metab"},{"issue":"9","key":"10.1016\/j.gim.2024.101242_bib37","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.3390\/genes11091091","article-title":"Biomarkers of Fabry nephropathy: review and future perspective","volume":"11","author":"Levstek","year":"2020","journal-title":"Genes (Basel)"},{"issue":"4","key":"10.1016\/j.gim.2024.101242_bib38","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1136\/jmedgenet-2014-102872","article-title":"Plasma globotriaosylsphingosine in relation to phenotypes of Fabry disease","volume":"52","author":"Smid","year":"2015","journal-title":"J\u00a0Med Genet"},{"issue":"1","key":"10.1016\/j.gim.2024.101242_bib39","doi-asserted-by":"crossref","first-page":"389","DOI":"10.3390\/cimb43010032","article-title":"Plasma globotriaosylsphingosine and \u03b1-galactosidase A activity as a combined screening biomarker for Fabry disease in a large Japanese cohort","volume":"43","author":"Maruyama","year":"2021","journal-title":"Curr Issues Mol Biol"},{"issue":"3","key":"10.1016\/j.gim.2024.101242_bib40","doi-asserted-by":"crossref","first-page":"155","DOI":"10.3390\/diagnostics10030155","article-title":"Elevated LysoGb3 concentration in the neuronopathic forms of mucopolysaccharidoses","volume":"10","author":"Baydakova","year":"2020","journal-title":"Diagnostics (Basel)"},{"issue":"1","key":"10.1016\/j.gim.2024.101242_bib41","first-page":"85","article-title":"Global incidence and prevalence of Gaucher disease: a targeted literature review","volume":"12","author":"Castillon","year":"2022","journal-title":"J\u00a0Clin Med"},{"issue":"1","key":"10.1016\/j.gim.2024.101242_bib42","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/s41572-018-0025-4","article-title":"Lysosomal storage diseases","volume":"4","author":"Platt","year":"2018","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.gim.2024.101242_bib43","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.cbpa.2019.10.006","article-title":"Glycosphingolipids and lysosomal storage disorders as illustrated by Gaucher disease","volume":"53","author":"Aerts","year":"2019","journal-title":"Curr Opin Chem Biol"},{"issue":"5","key":"10.1016\/j.gim.2024.101242_bib44","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1016\/j.bbalip.2013.11.004","article-title":"Gaucher disease and Fabry disease: new markers and insights in pathophysiology for two distinct glycosphingolipidoses","volume":"1841","author":"Ferraz","year":"2014","journal-title":"Biochim Biophys Acta"},{"issue":"1","key":"10.1016\/j.gim.2024.101242_bib45","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.jceh.2014.02.005","article-title":"Gaucher disease","volume":"4","author":"Nagral","year":"2014","journal-title":"J\u00a0Clin Exp Hepatol"},{"issue":"2","key":"10.1016\/j.gim.2024.101242_bib46","doi-asserted-by":"crossref","first-page":"441","DOI":"10.3390\/ijms18020441","article-title":"A\u00a0review of Gaucher disease pathophysiology, clinical presentation and treatments","volume":"18","author":"Stirnemann","year":"2017","journal-title":"Int J Mol Sci"},{"issue":"3","key":"10.1016\/j.gim.2024.101242_bib47","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1615\/CritRevOncog.2013006060","article-title":"Gaucher disease: a comprehensive review","volume":"18","author":"Rosenbloom","year":"2013","journal-title":"Crit Rev Oncog"},{"issue":"13","key":"10.1016\/j.gim.2024.101242_bib48","doi-asserted-by":"crossref","first-page":"4577","DOI":"10.3390\/ijms21134577","article-title":"Treatment efficiency in Gaucher patients can reliably be monitored by quantification of Lyso-Gb1 concentrations in dried blood spots","volume":"21","author":"Cozma","year":"2020","journal-title":"Int J Mol Sci"},{"issue":"5","key":"10.1016\/j.gim.2024.101242_bib49","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1515\/cclm-2019-0949","article-title":"LC-MS\/MS analysis of plasma glucosylsphingosine as a biomarker for diagnosis and follow-up monitoring in Gaucher disease in the Spanish population","volume":"58","author":"Ir\u00fan","year":"2020","journal-title":"Clin Chem Lab Med"},{"issue":"2","key":"10.1016\/j.gim.2024.101242_bib50","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/S1096-7192(03)00071-4","article-title":"Gaucher disease with parkinsonian manifestations: does glucocerebrosidase deficiency contribute to a vulnerability to parkinsonism?","volume":"79","author":"Tayebi","year":"2003","journal-title":"Mol Genet Metab"},{"issue":"26","key":"10.1016\/j.gim.2024.101242_bib51","doi-asserted-by":"crossref","first-page":"23594","DOI":"10.1074\/jbc.M300212200","article-title":"Glucosylceramide and glucosylsphingosine modulate calcium mobilization from brain microsomes via different mechanisms","volume":"278","author":"Lloyd-Evans","year":"2003","journal-title":"J\u00a0Biol Chem"},{"issue":"1-2","key":"10.1016\/j.gim.2024.101242_bib52","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.cccn.2004.02.018","article-title":"Correlation of surrogate markers of Gaucher disease. Implications for long-term follow up of enzyme replacement therapy","volume":"344","author":"Cabrera-Salazar","year":"2004","journal-title":"Clin Chim Acta"},{"issue":"11","key":"10.1016\/j.gim.2024.101242_bib53","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1002\/ajh.24491","article-title":"Glucosylsphingosine is a key biomarker of Gaucher disease","volume":"91","author":"Murugesan","year":"2016","journal-title":"Am J Hematol"},{"issue":"4","key":"10.1016\/j.gim.2024.101242_bib54","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/S1096-7192(02)00117-8","article-title":"Glucosylsphingosine accumulation in tissues from patients with Gaucher disease: correlation with phenotype and genotype","volume":"76","author":"Orvisky","year":"2002","journal-title":"Mol Genet Metab"},{"issue":"3","key":"10.1016\/j.gim.2024.101242_bib55","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1203\/01.PDR.0000049515.79882.94","article-title":"Myoclonic epilepsy in Gaucher disease: genotype-phenotype insights from a rare patient subgroup","volume":"53","author":"Park","year":"2003","journal-title":"Pediatr Res"},{"key":"10.1016\/j.gim.2024.101242_bib56","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.clinbiochem.2020.10.011","article-title":"Detection of glucosylsphingosine in dried blood spots for diagnosis of Gaucher disease by LC-MS\/MS","volume":"87","author":"Tang","year":"2021","journal-title":"Clin Biochem"},{"issue":"19","key":"10.1016\/j.gim.2024.101242_bib57","doi-asserted-by":"crossref","first-page":"7159","DOI":"10.3390\/ijms21197159","article-title":"Value of glucosylsphingosine (Lyso-Gb1) as a biomarker in Gaucher disease: a systematic literature review","volume":"21","author":"Revel-Vilk","year":"2020","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.gim.2024.101242_bib58","series-title":"GeneReviews","article-title":"Krabbe disease","author":"Orsini","year":"2000"},{"issue":"5","key":"10.1016\/j.gim.2024.101242_bib59","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1007\/s10545-015-9822-z","article-title":"Measurement of psychosine in dried blood spots\u2014a possible improvement to newborn screening programs for Krabbe disease","volume":"38","author":"Turgeon","year":"2015","journal-title":"J\u00a0Inherit Metab Dis"},{"issue":"3","key":"10.1016\/j.gim.2024.101242_bib60","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.ymgme.2017.05.015","article-title":"Psychosine, a marker of Krabbe phenotype and treatment effect","volume":"121","author":"Escolar","year":"2017","journal-title":"Mol Genet Metab"},{"key":"10.1016\/j.gim.2024.101242_bib61","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.cca.2019.03.009","article-title":"Galactosylsphingosine does not interfere with the quantitation of plasma glucosylsphingosine levels in Gaucher patients","volume":"494","author":"Chuang","year":"2019","journal-title":"Clin Chim Acta"},{"issue":"6","key":"10.1016\/j.gim.2024.101242_bib62","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1038\/s41436-020-0764-y","article-title":"The critical role of psychosine in screening, diagnosis, and monitoring of Krabbe disease","volume":"22","author":"Guenzel","year":"2020","journal-title":"Genet Med"},{"issue":"1","key":"10.1016\/j.gim.2024.101242_bib63","first-page":"37","article-title":"Diurnal variability of glucose tetrasaccharide (Glc4) excretion in patients with glycogen storage disease type III","volume":"58","author":"Young","year":"2021","journal-title":"JIMD Rep"},{"issue":"7","key":"10.1016\/j.gim.2024.101242_bib64","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1373\/clinchem.2011.178319","article-title":"Rapid ultraperformance liquid chromatography-tandem mass spectrometry assay for a characteristic glycogen-derived tetrasaccharide in Pompe disease and other glycogen storage diseases","volume":"58","author":"Sluiter","year":"2012","journal-title":"Clin Chem"},{"key":"10.1016\/j.gim.2024.101242_bib65","article-title":"Urine glucose tetrasaccharide: a good biomarker for glycogenoses type II and III? A study of the French cohort","volume":"23","author":"Piraud","year":"2020","journal-title":"Mol Genet Metab Rep"},{"issue":"3","key":"10.1016\/j.gim.2024.101242_bib66","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1016\/j.ncl.2014.04.010","article-title":"Pompe disease: literature review and case series","volume":"32","author":"Dasouki","year":"2014","journal-title":"Neurol Clin"},{"key":"10.1016\/j.gim.2024.101242_bib67","series-title":"GeneReviews","article-title":"Pompe disease","author":"Leslie","year":"2007"},{"issue":"11","key":"10.1016\/j.gim.2024.101242_bib68","doi-asserted-by":"crossref","first-page":"2543","DOI":"10.1038\/s41436-019-0527-9","article-title":"Clinical characteristics and genotypes in the ADVANCE baseline data set, a comprehensive cohort of US children and adolescents with Pompe disease","volume":"21","author":"Kishnani","year":"2019","journal-title":"Genet Med"},{"issue":"4","key":"10.1016\/j.gim.2024.101242_bib69","doi-asserted-by":"crossref","first-page":"89","DOI":"10.3390\/ijns6040089","article-title":"Newborn screening for Pompe disease: Pennsylvania experience","volume":"6","author":"Ficicioglu","year":"2020","journal-title":"Int J Neonatal Screen"},{"key":"10.1016\/j.gim.2024.101242_bib70","first-page":"67","article-title":"Baseline urinary glucose tetrasaccharide concentrations in patients with infantile- and late-onset Pompe disease identified by newborn screening","volume":"19","author":"Chien","year":"2015","journal-title":"JIMD Rep"},{"issue":"2","key":"10.1016\/j.gim.2024.101242_bib71","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/S0003-2697(03)00056-3","article-title":"Analysis of a glucose tetrasaccharide elevated in Pompe disease by stable isotope dilution-electrospray ionization tandem mass spectrometry","volume":"316","author":"Young","year":"2003","journal-title":"Anal Biochem"},{"issue":"4","key":"10.1016\/j.gim.2024.101242_bib72","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.ymgme.2005.03.010","article-title":"Glucose tetrasaccharide as a biomarker for monitoring the therapeutic response to enzyme replacement therapy for Pompe disease","volume":"85","author":"An","year":"2005","journal-title":"Mol Genet Metab"},{"issue":"1","key":"10.1016\/j.gim.2024.101242_bib73","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1002\/ajmg.c.31320","article-title":"Assessing disease severity in Pompe disease: the roles of a urinary glucose tetrasaccharide biomarker and imaging techniques","volume":"160C","author":"Young","year":"2012","journal-title":"Am J Med Genet C Semin Med Genet"},{"issue":"2","key":"10.1016\/j.gim.2024.101242_bib74","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1007\/s10545-011-9360-2","article-title":"Urine analysis of glucose tetrasaccharide by HPLC; a useful marker for the investigation of patients with Pompe and other glycogen storage diseases","volume":"35","author":"Manwaring","year":"2012","journal-title":"J\u00a0Inherit Metab Dis"},{"issue":"1","key":"10.1016\/j.gim.2024.101242_bib75","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/0009-8981(88)90172-6","article-title":"Urinary excretion of a glucose-containing tetrasaccharide. A parameter for increased degradation of glycogen","volume":"176","author":"Kumlien","year":"1988","journal-title":"Clin Chim Acta"},{"issue":"RR-2","key":"10.1016\/j.gim.2024.101242_bib76","first-page":"1","article-title":"Good laboratory practices for biochemical genetic testing and newborn screening for inherited metabolic disorders","volume":"61","year":"2012","journal-title":"MMWR Recomm Rep"},{"key":"10.1016\/j.gim.2024.101242_bib77","article-title":"Effect of ambroxol chaperone therapy on glucosylsphingosine (Lyso-Gb1) levels in two Canadian patients with type 3 Gaucher disease","volume":"20","author":"Charkhand","year":"2019","journal-title":"Mol Genet Metab Rep"},{"issue":"2","key":"10.1016\/j.gim.2024.101242_bib78","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1093\/brain\/awac379","article-title":"Venglustat combined with imiglucerase for neurological disease in adults with Gaucher disease type 3: the LEAP trial","volume":"146","author":"Schiffmann","year":"2023","journal-title":"Brain"},{"key":"10.1016\/j.gim.2024.101242_bib79","series-title":"Dried Blood Spot Specimen Collection for Newborn Screening","year":"2021"},{"key":"10.1016\/j.gim.2024.101242_bib80","series-title":"4th ed. CLSI guideline C24","article-title":"Statistical Quality Control for Quantitative Measurement Procedures: Principles and Definitions","year":"2016"},{"key":"10.1016\/j.gim.2024.101242_bib81","series-title":"Tietz Textbook of Clinical Chemistry and Molecular Diagnostics","first-page":"121","article-title":"Quality control of the analytical examination process","author":"Miller","year":"2018"},{"key":"10.1016\/j.gim.2024.101242_bib82","series-title":"Using Proficiency Testing and Alternative Assessment to Improve Medical Laboratory Quality","year":"2016"},{"key":"10.1016\/j.gim.2024.101242_bib83","series-title":"Defining, Establishing, and Verifying Reference Intervals in the Clinical Laboratory; Approved Guideline","year":"2008"},{"issue":"5","key":"10.1016\/j.gim.2024.101242_bib84","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0127048","article-title":"Nano-LC-MS\/MS for quantification of Lyso-Gb3 and its analogues reveals a useful biomarker for Fabry disease","volume":"10","author":"Sueoka","year":"2015","journal-title":"PLoS One"},{"issue":"7","key":"10.1016\/j.gim.2024.101242_bib85","doi-asserted-by":"crossref","first-page":"3476","DOI":"10.1021\/ac404000d","article-title":"Multiplex tandem mass spectrometry analysis of novel plasma lyso-Gb3-related analogues in Fabry disease","volume":"86","author":"Boutin","year":"2014","journal-title":"Anal Chem"},{"key":"10.1016\/j.gim.2024.101242_bib86","first-page":"17.23.1","article-title":"Tandem mass spectrometry quantitation of Lyso-Gb3 and six related analogs in plasma for Fabry disease patients","volume":"90","author":"Boutin","year":"2016","journal-title":"Curr Protoc Hum Genet"},{"issue":"17","key":"10.1016\/j.gim.2024.101242_bib87","article-title":"Fabry disease biomarkers: analysis of urinary Lyso-Gb3 and seven related analogs using tandem mass spectrometry","volume":"90","author":"Lavoie","year":"2016","journal-title":"Curr Protoc Hum Genet"},{"issue":"3","key":"10.1016\/j.gim.2024.101242_bib88","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1021\/ac303033v","article-title":"Multiplex analysis of novel urinary lyso-Gb3-related biomarkers for Fabry disease by tandem mass spectrometry","volume":"85","author":"Lavoie","year":"2013","journal-title":"Anal Chem"},{"issue":"1","key":"10.1016\/j.gim.2024.101242_bib89","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1006\/abbi.1993.1353","article-title":"Accumulation of tissue glucosylsphingosine in Gaucher-like mouse induced by the glucosylceramidase inhibitor cyclophellitol","volume":"304","author":"Atsumi","year":"1993","journal-title":"Arch Biochem Biophys"},{"issue":"23","key":"10.1016\/j.gim.2024.101242_bib90","doi-asserted-by":"crossref","first-page":"7358","DOI":"10.3390\/molecules26237358","article-title":"A\u00a0rapid and simple UHPLC-MS\/MS method for quantification of plasma globotriaosylsphingosine (lyso-Gb3)","volume":"26","author":"Perrone","year":"2021","journal-title":"Molecules"},{"key":"10.1016\/j.gim.2024.101242_bib91","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.cca.2013.01.017","article-title":"Determination of psychosine concentration in dried blood spots from newborns that were identified via newborn screening to be at risk for Krabbe disease","volume":"419","author":"Chuang","year":"2013","journal-title":"Clin Chim Acta"},{"key":"10.1016\/j.gim.2024.101242_bib92","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/978-1-0716-2565-1_25","article-title":"Plasma lysosphingolipid biomarker measurement by liquid chromatography tandem mass spectrometry","volume":"2546","author":"Stauffer","year":"2022","journal-title":"Methods Mol Biol"},{"issue":"3","key":"10.1016\/j.gim.2024.101242_bib93","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1515\/cclm-2016-0340","article-title":"Diagnosis of sphingolipidoses: a new simultaneous measurement of lysosphingolipids by LC-MS\/MS","volume":"55","author":"Polo","year":"2017","journal-title":"Clin Chem Lab Med"},{"issue":"7","key":"10.1016\/j.gim.2024.101242_bib94","doi-asserted-by":"crossref","DOI":"10.1002\/bmc.4235","article-title":"A\u00a0HILIC-MS\/MS method for simultaneous quantification of the lysosomal disease markers galactosylsphingosine and glucosylsphingosine in mouse serum","volume":"32","author":"Sidhu","year":"2018","journal-title":"Biomed Chromatogr"},{"key":"10.1016\/j.gim.2024.101242_bib95","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.cca.2020.10.007","article-title":"Combined analysis of plasma or serum glucosylsphingosine and globotriaosylsphingosine by UPLC-MS\/MS","volume":"511","author":"Beasley","year":"2020","journal-title":"Clin Chim Acta"},{"key":"10.1016\/j.gim.2024.101242_bib96","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpba.2022.114852","article-title":"Highly-sensitive simultaneous quantitation of glucosylsphingosine and galactosylsphingosine in human cerebrospinal fluid by liquid chromatography\/tandem mass spectrometry","volume":"217","author":"Matsumoto","year":"2022","journal-title":"J\u00a0Pharm Biomed Anal"},{"issue":"2","key":"10.1016\/j.gim.2024.101242_bib97","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1002\/bms.1200030202","article-title":"Quantitation of a urinary tetrasaccharide by gas chromatography and mass spectrometry","volume":"3","author":"Lennartson","year":"1976","journal-title":"Biomed Mass Spectrom"},{"issue":"1","key":"10.1016\/j.gim.2024.101242_bib98","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1093\/clinchem\/48.1.131","article-title":"Determination of oligosaccharides in Pompe disease by electrospray ionization tandem mass spectrometry","volume":"48","author":"Rozaklis","year":"2002","journal-title":"Clin Chem"}],"container-title":["Genetics in Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S109836002400176X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S109836002400176X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T01:04:34Z","timestamp":1767229474000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S109836002400176X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":98,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["S109836002400176X"],"URL":"https:\/\/doi.org\/10.1016\/j.gim.2024.101242","relation":{},"ISSN":["1098-3600"],"issn-type":[{"value":"1098-3600","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Biomarker testing for lysosomal diseases: A technical standard of the American College of Medical Genetics and Genomics (ACMG)","name":"articletitle","label":"Article Title"},{"value":"Genetics in Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.gim.2024.101242","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 American College of Medical Genetics and Genomics. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"101242"}}